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Abstract: Macromolecular gadolinium (Gd)(III) complexes have a prolonged blood circulation
time and can preferentially accumulate in solid tumors, depending on the tumor blood vessel
hyperpermeability, resulting in superior contrast enhancement in magnetic resonance (MR)
cardiovascular imaging and cancer imaging as shown in animal models. Unfortunately, safety
concerns related to these agents’ slow elimination from the body impede their clinical
development. Polydisulfide Gd(III) complexes have been designed and developed as
biodegradable macromolecular magnetic resonance imaging (MRI) contrast agents to facilitate
the clearance of Gd(III) complexes from the body after MRI examinations. These novel agents
can act as macromolecular contrast agents for in vivo imaging and excrete rapidly as low-
molecular-weight agents. The rationale and recent development of the novel biodegradable
contrast agents are reviewed here. Polydisulfide Gd(III) complexes have relatively long blood
circulation time and gradually degrade into small Gd(III) complexes, which are rapidly excreted
via renal filtration. These agents result in effective and prolonged in vivo contrast enhancement
in the blood pool and tumor tissue in animal models, yet demonstrate minimal Gd(III) tissue
retention as the clinically used low-molecular-weight agents. Structural modification of the
agents can readily alter the contrast-enhancement kinetics. Polydisulfide Gd(III) complexes
are promising for further clinical development as safe, effective, biodegradable macromolecular
MRI contrast agents for cardiovascular and cancer imaging, and for evaluation of therapeutic
response.
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Introduction
Magnetic resonance imaging (MRI) is a clinical diagnostic modality based on
differences in the longitudinal and transverse relaxation rates (1/T1 or 1/T2) of water
protons in different tissues (Liang and Lauterbur 2000). MRI signal intensity reflects
the value of the relaxation rate of tissues. Contrast agents have been developed and
used to enhance MR image contrast and to improve diagnostic accuracy. Paramagnetic
metal chelates, eg, Gd(III), Fe(III), and Mn(II) complexes, can alter the relaxation
rate of the surrounding water protons to allow for more effective MRI contrast
enhancement (Caravan et al 1999). Gadolinium (Gd)(III) ions have seven unpaired
electrons and a large paramagnetic moment. Gd(III) chelates with high stability, eg,
Gd-DTPA, Gd-DOTA, or their derivatives, have been mainly developed as MRI
contrast agents, which increase both 1/T1 and 1/T2 relaxivities (Weinmann et al 1984;
Magerstadt et al 1986; Hayne et al 1989). Currently, Gd-containing contrast agents
are used in approximately 30% of MRI examinations.
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The Gd chelates approved for human use are nonspecific
and have unfavorable pharmacokinetics. These low-
molecular-weight agents rapidly extravasate from the
vasculature and nondiscriminatively distribute in the
extracellular space. The agents have a very short blood half-
life and a short time window for contrast-enhanced imaging.
In many situations it is difficult to estimate the timing for
optimal imaging, impeding accurate diagnostic imaging.
Macromolecular Gd(III) complexes have been developed
to improve contrast-enhanced MR imaging. Macromolecular
contrast agents are prepared by the conjugation of Gd(III)
DTPA, DOTA complexes, or their derivatives to synthetic
polymers (Schuhmann-Giampieri et al 1991; Bogdanov et
al 1993; Wiener et al 1994; Kobayashi and Brechbiel 2004;
Langereis 2004) or natural macromolecules (Lauffer and
Brady 1985; Wang et al 1990; Sirlin et al 2004), or by
copolymerization of the low-molecular-weight contrast
agents (Kellar et al 1997; Ladd et al 1999; Duarte et al 2001).
These agents have a long blood circulation time and can
preferentially accumulate in solid tumor tissue depending
on the hyperpermeability of the tumor vasculature
(Gerlowski and Jain 1986; Hobbs et al 1998). As a result,
they provide superior contrast enhancement in the blood
pool and in solid tumor tissue in animal models (Gossmann
et al 1999; Turetschek et al 2001; de Lussanet et al 2005).
A number of macromolecular Gd(III) complexes have
been investigated as blood-pool contrast agents (Schuhmann-
Giampieri et al 1991; Bogdanov et al 1993; Shibata et al
1995; Van Beers et al 1995; Roberts et al 1997; Kobayashi
et al 2001b; Li et al 2001; Lee 2003; Sirlin et al 2004).
These agents show molecular-weight-dependent or size-
dependent plasma half-lives (Vexler et al 1994; Kobayashi
et al 2001a,b), and agents with higher molecular weights
and longer blood half-life produced the better contrast
enhanced vascular imaging. Higher-molecular-weight
chelates were prepared to increase their intravascular
retention time for longer and clearer visualization of the
neovascularity of neoplastic tissue (Weissleder et al 2001).
Macromolecular agents with relatively high molecular
weight (> 20 kDa, linear size) have a potential to detect and
characterize individual tumors more specifically and
accurately due to their ability to measure tumor
microvascular permeability, microvascular density, and
vascular recruitment. For example, albumin-(Gd-DTPA)
(92 kDa) does not accumulate in benign tumors, but can
gradually diffuse into the interstitial spaces of malignant
tumors, which may be useful to accurately differentiate
between these tumors (Gossmann et al 1999; van Dijke
1996).
Although macromolecular Gd(III) complexes have clear
advantages as blood-pool contrast agents, their slow body
clearance is also a disadvantage with respect to toxicity.
Free Gd(III) ions are highly toxic, with an LD50 as low as
0.5 mmol/kg in rat models (Weinmann et al 1984). The
dissociation of Gd(III) complexes and release of Gd(III)
ions can be lethally toxic (Cacheris et al 1990). The longer
body retention time increases the probability of metabolism
of the macromolecular complexes and release of Gd(III)
ions. The clearance rate decreases with the increase of
molecular weight of the contrast agents (Kobayashi 2003).
It has been reported that a Gd-DTPA polypropyleneimine
dendrimer (generation 2) conjugate (7 kDa) resulted in the
retention of 45% of injected dose in rats 14 days after
injection (Wang 2003). The conjugation of Gd-DO3A to
carboxylmethyl hydroxylethyl starch resulted in a
macromolecular agent (72 kDa) that had about 47% of
injected dose detected in rat body 7 days after the injection
(Helbich et al 2000). Because of this safety concern, clinical
development of macromolecular contrast agents has been
limited.
Biodegradable polymers including poly(L-lysine),
dextrans, and proteins have been used in the synthesis of
macromolecular contrast agents. However, in vivo
degradation of these materials takes place primarily in
intracellular enzymatic compartments. MRI contrast agents
are mostly extracellular agents and have low cellular uptake.
In addition, the extensive chemical conjugation on the
polymers can significantly reduce their biodegradability
(Crepon et al 1991). Consequently, contrast agents prepared
from these polymers have longer body retention times and
result in significant accumulation of Gd ions in tissues
(Bogdanov et al 1993; Franano et al 1995; Helbich et al
2000). Innovative approaches are needed for the design and
development of safe, effective macromolecular contrast
agents for clinical application.
We have recently designed and developed novel
extracellular biodegradable macromolecular Gd(III)
complexes based on polydisulfides to facilitate Gd(III)
elimination and to minimize its tissue retention (Lu et al
2004). These complexes act as macromolecular agents for
MR contrast enhancement and rapidly excrete as low-
molecular-weight Gd(III) chelates after the macromolecules
are broken down by the endogenous thiols via the disulfide-
thiol exchange reaction. Here, we summarize the rationale
of the biodegradable macromolecular contrast agents, theirInternational Journal of Nanomedicine 2006:1(1) 33
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physicochemical and biological properties, and in vivo
contrast enhancement in animal models.
Rationale of polydisulfide
macromolecular MRI contrast
agents
The ideal MRI contrast agent would be an agent able to
accumulate in the tissue of interest long enough for imaging
with conventional or dynamic MRI, then rapidly clear from
the body. Currently available MRI contrast agents are
primarily low-molecular-weight Gd(III) chelates, which
have transient tissue retention and clear rapidly from the
body. Macromolecular Gd(III) complexes exhibit long tissue
retention and excrete slowly. We hypothesize that the
incorporation of biodegradable structures into the backbone
of macromolecules containing Gd(III) chelates can result
in MRI contrast agents that will provide sufficient blood
pool and tissue retention for effective contrast enhanced MR
imaging. The structures will then react with biomolecules
present in plasma or tissues to break down the macro-
molecules into smaller Gd(III) complexes that can be readily
excreted (Lu et al 2004).
The disulfide-thiol exchange reaction plays a crucial role
in biological systems. Free thiols including cysteine,
glutathione (GSH), cysteinylglycine (Cys-Gly), and
homocysteine are important endogenous biomolecules, with
a total concentration of 15 µM in human blood plasma and
about 10 mM in the cytoplasm (Andersson et al 1995;
Deneke 2000). We have incorporated disulfide bonds into
the backbone of macromolecular Gd(III) complexes to
prepare biodegradable macromolecular MRI contrast agents.
The disulfide bonds in the polymer chains can be readily
cleaved by the thiols via disulfide-thiol exchange reaction
to break down the macromolecules into smaller Gd(III)
complexes, which can be excreted through renal filtration.
Since Gd(III) chelates are mostly extracellular agents and
the plasma thiol concentration is low, the degradation of
the macromolecular agents is a slow process, which allows
the agents to reside for an acceptable period in the circulation
for effective contrast-enhanced MR imaging.
The concept of extracellular biodegradable macro-
molecular MRI contrast agents was validated with the first
polydisulfide agent, Gd-DTPA cystamine copolymers
(GDCC) (Lu et al 2004). GDCC was gradually degraded
into smaller Gd(III) complexes by the cleavage of the
disulfide bonds in the polymer backbone via the disulfide-
thiol exchange reaction in the presence of 15 µM cysteine
(Figure 1). The structures of degradation products were
verified by MALDI-TOF mass spectrometry. GDCC
resulted in more significant and prolonged contrast
enhancement in the cardiovascular systems in rat than a
clinical agent, Gd-(DTPA-BMA), and excreted rapidly via
renal filtration. Metabolic degradation products were
identified by mass spectrometry in the rat urine samples.
The structure of the polydisulfides can be readily
modified to alter the physicochemical properties, pharmaco-
kinetics, and in vivo contrast enhancement of the
biodegradable MRI contrast agents. Functional groups have
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Figure 2 Structure of Gd-DTPA cystine copolymers (GDCP) and modified
GDCP.
Abbreviations: OEt, ethoxy group; PEG, poly(ethylene glycol); GDCEP, Gd-
DTPA cystine diethyl ester copolymer.
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Figure 1 Degradation of Gd-DTPA cystamine copolymers (GDCC) in the
presence of cysteine.
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been introduced around the disulfide bonds by replacing
cystamine with cystine. The chemistry of cystine is more
versatile and the carboxylic groups in cystine can be further
modified to design and prepare biodegradable macro-
molecular contrast agents with different properties (Mohs
et al 2004; Zong et al 2005). Different substituents have
been attached to cystine (Figure 2), and the modified agents
demonstrated different degradability, pharmacokinetics, and
in vivo contrast enhancement. The chemistry, physico-
chemical and pharmaceutical properties, and in vivo contrast
enhancement of the polydisulfide agents are discussed in
the following sections.
Synthesis of polydisulfide Gd(III)
complexes
The synthetic procedure of polydisulfide Gd(III) complexes
is described in Figure 3 with GDCC as an example. DTPA
dianhydride is first copolymerized with a disulfide-
containing diamine, eg, cystamine or cystine, by
condensation copolymerization under basic conditions to
give a polymeric ligand. Different solvents and bases can
be used according to the solubility of disulfide monomers.
Dimethyl sulfoxide was used as the solvent and triethyl-
amine as the base for the monomers soluble in organic
solvent. For cystine, which is not soluble in organic solvent,
the copolymerization was performed in aqueous solution
of sodium carbonate or sodium hydroxide. Polydisulfide
Gd(III) complexes are then prepared by the complexation
of the polymeric ligands with GdCl3 or Gd(OAc)3 at
pH 5–6. The pH of the reaction mixture with GdCl3
decreases significantly during the complexation because of
the release of HCl, and NaOH is added to maintain the pH
at 5–6. There is no significant change of pH in the reaction
with Gd(OAc)3.
The molecular weight of polydisulfides from the
condensation copolymerization can be as high as
100 000 Da. There is a significant decrease of apparent
molecular weight of copolymers after complexation with
Gd(III) because of the change of hydrodynamic volume of
the copolymers after complexation. The molecular weights
of some paramagnetic copolymers are listed in Table 1. The
polydisulfides are negatively charged and have a large
hydrodynamic volume. Once the polydisulfide ligands
chelate with Gd
3+, the polydisulfide Gd(III) complexes are
neutral or less charged and have reduced hydrodynamic
volume.
The structure of polydisulfide Gd(III) complexes have
been modified by grafting PEG of different lengths to the
carboxylic groups in Gd-DTPA cystine copolymers (GDCP)
(Mohs et al 2004, 2005). Monomethoxy-PEG amine
Table 1 Physicochemical parameters of some polydisulfide Gd(III) complexes
Polymeric Molecular weight (kDa) Relaxivity PEGylation
contrast agent Mw Mn Mw/Mn mM
–1sec
–1 PEG size (Da) PEG/Gd
GDCC 17.7 15.0 1.2 4.4 (1.5T)
35.0 27.0 1.3 6.3 (1.5T)
GDCP 10.1 10.0 1.0 5.5 (3.0T)
GDCEP 10.2 9.4 1.1 5.9 (3.0T)
PEGa-GDCP 24.5 21.0 1.2 16.3 (3.0T) 2000 0.33
PEGb-GDCP 22.9 19.9 1.2 12.7 (3.0T) 2000 0.76
PEG2000-GDCP 37.7 28.5 1.3 8.7 (3.0T) 2000 1.2
PEG1000-GDCP 37.8 31.1 1.2 7.8 (3.0T) 1000 1.3
PEG550-GDCP 33.7 30.8 1.1 7.8 (3.0T) 550 1.3
Abbreviations: PEG, polyethylene glycol; GDCC, Gd-DTPA cystamine copolymer; GDCP, Gd-DTPA cystine copolymer; GDCEP, Gd-DTPA cystine diethyl ester
copolymer; Mw, averaged molecular weight; Mn, averaged molecular number.
Figure 3 Synthesis of the polydisulfide agent Gd-DTPA cystamine copolymers
(GDCC).
Abbreviations: DMSO, dimethyl sulfoxide; TEA, triethylanine.
N
N N
COO-
N
H
O O
S
S
H
N
COO- COO-
n
H2N
S
NH2
S ON NO N
COOH
N
N N Gd3+
COO-
N
H
O O
S
S
H
N
COO- COO-
n
+
TEA
DMSO
Gd(OAc)3
pH = 5.5
O
O
O
O
 International Journal of Nanomedicine 2006:1(1) 35
Paramagnetic polydisulfides
(MPEG-NH2) was attached to GDCP in the presence of a
coupling agent, 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride, in aqueous solution (Figure 4).
The grafting degree can be readily manipulated by altering
the ratio of mPEG-NH2 to GDCP. The modification
increases apparent molecular weights of the copolymers at
a low grafting degree depending on the size of PEG. Further
increase of grafting degree with PEG of the same size does
not further increase apparent molecular weight of the
copolymers.
The coordination feature of Gd(III) in the polydisulfide
complexes is the same as that in Gd-(DTPA-BMA), a clinical
MRI contrast agent. The Gd(III) is coordinated to 3 tertiary
amine nitrogen atoms, 3 carboxylic groups, and 2 carbonyl
groups of the amides of the DTPA bisamide. Gd-(DTPA-
BMA) is a nonionic agent and has low acute toxicity in
mice (LD50 = 14.8 mmol/kg ) because of high stability and
low transmetallation with Ca2+ (Cacheris et al 1990).
Relaxivity of polydisulfide Gd(III)
complexes
The paramagnetic chelates decrease both T1 and T2
relaxation times, or increase the relaxation rates of
surrounding water protons, resulting in increased signal
intensity in T1-weighted imaging and decreased signal
intensity in T2-weighted imaging. The chelates have a more
significant effect on the relaxation rate of water protons in
the coordination sphere of Gd(III) ions, less effect on water
molecules immediately surrounding the chelate, and little
direct effect on the bulk water molecules. Therefore, an
effective Gd(III) chelate contrast agent should have at least
one coordination site for water molecules. The complexed
water molecule rapidly exchanges with bulk water, resulting
in efficient relaxation of bulk water. The net change of the
relaxation rate of water protons depends on the concentration
of Gd(III) chelates and water exchange rate at the
coordination site. Relaxivity is the measurement of the
efficiency of a contrast agent to change the
relaxation rate and can be determined from the equation
(1/Ti)obs = (1/Ti)d + ri[Gd] (i = 1, 2), where (1/Ti)obs refers to
the measured relaxation rate, (1/Ti)d the relaxation rate
without a contrast agent, and ri the T1 or T2 relaxivity.
Gd(III) chelates are primarily used in T1-weighted,
contrast-enhanced MRI. High r1 of Gd(III) chelates will
result in strong relaxation or contrast enhancement.
Polydisulfide Gd(III) complexes have higher T1 relaxivity
than Gd-(DTPA-BMA) and the relaxivity varies based on
the structure of the complexes (Table 1). GDCC, GDCP,
and Gd-DTPA cystine diethyl ester copolymer (GDCEP)
have similar relaxivity in the range of 4.5–6.5 mM
–1sec
–1. It
appears that the degree of PEGylation in poly(ethylene
glycol) (PEG)-modified GDCP has a more significant
impact on its relaxivity than the PEG chain length. PEG-
GDCP copolymers with different PEG lengths have similar
relaxivity at the same grafting degree (Mohs et al 2005).
For PEG-GDCP copolymers with the same PEG length
(2000 Da), the increase of grafting degree significantly
decreases relaxivity. The T1 relaxivity of PEG2000-GDCP
with grafting ratios of 0.33, 0.76, and 1.2 mM
–1s
–1 decreases
from 16.3 to 12.7, and 8.73 mM
–1s
–1, respectively. A high
density of PEG on the backbones of the copolymers may
interfere with the interaction of water molecules to the
Gd(III) complexes because PEG can associate with water
molecules via hydrogen bonding (Mohs et al 2004).
Degradability of polydisulfide
Gd(III) complexes
Polydisulfide Gd(III) complexes with different structures
demonstrate different degradation characteristics in the
presence of cysteine. There was no degradation of GDCP
in the incubation with 15 µM cysteine for 6 hours at
pH 7.4 and 37 ºC. GDCC gradually degraded under the
same conditions and its molecular weight decreased
approximately 28%, 33%, and 50% at 5, 15, and 60 minutes
Figure 4 Synthesis of PEGylated Gd-DTPA cystine copolymer (GDCP).
Abbreviations: MPEG-NH2, monomethoxy-PEG amine; NHS, N-hydroxyl-
succinimide; EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride.
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in the reaction (Lu et al 2004). The degradation of GDCEP
was relatively slow in the first 60 minutes of incubation
compared with GDCC, and its molecular weight decreased
approximately 6%, 11%, and 24% at 5, 15, and 60 minutes.
Both GDCC and GDCEP degraded into smaller oligomers
and complexes at 6 hours (Zong et al 2005). Figure 5 shows
size exclusion chromatograms of GDCEP in the incubation
with 15 µM cysteine at pH 7.4 and 37 ºC. All three
macromolecular agents degraded more rapidly at higher
cysteine concentration (150 µM) and completely degraded
into the smallest repeat units in the incubation with an excess
of cysteine, which was verified by mass spectrometry. GDCP
and GDCEP are more sterically hindered around the
disulfide bonds than GDCC, resulting in slower degradation.
GDCP also has negative charges around the disulfide bonds
at neutral pH, which further impede the access of the
negatively charged cysteine to the disulfide bonds (Hupe
and Wu 1980). Therefore, little reduction of the disulfide
bonds in GDCP occurs at low cysteine concentrations.
The modification of GDCP also resulted in macro-
molecular agents with different degradability based on the
length of PEG chains (Mohs et al 2004, 2005). The PEG-
modified GDCP was stable at low cysteine concentration
(circa 10 µM), similar to GDCP, and degraded with increased
cysteine concentration. It appears that GDCP modified with
short PEG chains degraded more rapidly than that with
long chains. The structural modification resulted in
macromolecular agents with different degradability towards
the disulfide-thiol exchange reaction, which may have
different pharmacokinetic properties and in vivo contrast
enhancement.
Pharmacokinetics and excretion of
polydisulfide Gd(III) complexes
Polydisulfide Gd(III) complexes should be able to circulate
in the vasculature for an acceptable time window for
effective contrast-enhanced MR imaging and then clear from
the body with minimal long-term tissue retention of toxic
Gd(III) ions. Pharmacokinetic data are the quantitative
measurement of the circulation, excretion, and retention of
the biodegradable macromolecular contrast agents in the
body. A pharmacokinetic study showed that the low-
molecular-weight agent Gd-(DTPA-BMA) rapidly extravasated
from the vasculature, while GDCC had a higher plasma
concentration in the first few minutes (approximately 5–15
minutes) post injection at the same dose (0.1 mmol-Gd/kg)
in rats (Figure 6). The size of the biodegradable macro-
molecular agent affected the initial plasma concentration
of the agent, but not the clearance from the vasculature.
GDCC with high molecular weight (Mw = 60 000 Da) had a
higher plasma concentration in the initial period (circa 5
minutes) after the injection than GDCC with low molecular
weight (Mw = 18 000 Da). The plasma concentration of
GDCC with both molecular weights reached the same level
at 20 minutes post injection. Because the breakdown of the
macromolecules is gradual, GDCC of the high molecular
weight may produce relatively large molecules and remain
in the blood at high concentration in the early stages of
degradation. The large molecules eventually degrade into
smaller complexes that are readily cleared via renal filtration.
Most of the degradation products were cleared in the
urine via renal glomerular filtration and more than 50% of
injected GDCC was excreted in the first 4 hours post-
Figure 6 Plasma pharmacokinetics of Gd(III) complexes in rats after
intravenous injection of Gd-(DTPA-BMA) (S), GDCC-18 (18 kDa, ), and
GDCC-60 (60 kDa, ¡) at a dose of 0.1 mmol-Gd/kg
Abbreviations: GDCC, GD-DTPA cystamine copolymer.
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injection, similar to Gd-(DTPA-BMA). Consequently, rapid
degradation and excretion of GDCC resulted in minimal
retention of Gd(III) in the major organs and tissues 10 days
post-injection, which was at the same level as Gd-(DTPA-
BMA) (Wang et al 2005). The retention was much lower
than that of other macromolecular Gd(III) complexes. For
example, carboxymethyl hydroxyethyl starch-(Gd-DO3A)
still had approximately 47% of injected dose in the body of
experimental animals seven days after injection (Helbich el
al 2000).
The degradation products of GDCC in the urine samples
were identified as monomeric and oligomeric Gd(III)
complexes by mass spectrometry. It appears that the in vivo
degradation of the polydisulfide Gd(III) complexes was
more complicated than the simple disulfide-thiol exchange
reaction. Most of the Gd(III) complexes identified in the
mass spectra were further metabolized after the cleavage of
the disulfide bonds. The degradation products have a mass
higher than the molecular weight of Gd-DTPA
(Mw = 547.6 Da), the basic chelating unit of the agent,
suggesting that the agent was excreted as stable Gd(III)
chelates after degradation. These results have demonstrated
that the polydisulfide agents have a relatively long blood
circulation as macromolecules in the blood pool at the early
stage after injection and then degrade into smaller Gd(III)
complexes that excrete rapidly from the body.
In vivo MRI contrast enhancement
The polydisulfide Gd(III) complexes present superior
contrast enhancement in the cardiovascular systems and
tumor tissue compared with the low molecular-weight agent,
Gd-(DTPA-BMA), as shown in animal models. Figure 7
shows the 3D maximum-intensity-projection (MIP),
contrast-enhanced MR images of rats with Gd-(DTPA-
BMA) and GDCC with molecular weights of 18 000 and
60 000 Da (0.1 mmol-Gd/kg). GDCC of both molecular
weights resulted in strong contrast enhancement in rat heart
and vasculature at 2 minutes post injection and the signal
intensity gradually decreased. Gd-(DTPA-BMA) was
rapidly extravasated from the vasculature and the contrast
enhancement was much less at 2 minutes post-injection than
with GDCC. GDCC with higher molecular weight resulted
in more significant contrast enhancement in the small blood
vessels than GDCC with lower molecular weight. Strong
contrast enhancement was observed in rat kidneys and then
the urinary bladder with GDCC, indicating that the
biodegradable macromolecular agent was eliminated from
renal filtration and accumulated in the urinary bladder. The
contrast enhancement in the cardiovascular system returned
to background levels at 15 minutes post-injection while the
signal intensity in the bladder significantly increased.
Structural modification of polydisulfide agents altered
in vivo contrast enhancement. PEGylation of GDCP resulted
in more significant and prolonged contrast enhancement in
the blood pool than GDCP. Both grafting ratio and PEG
size have a significant impact on contrast enhancement
profile. PEG2000-GDCP at a grafting ratio of 0.76 produced
Figure 7 Three-dimensional maximum intensity projection (MIP) MR images of
rats before (a) and 2 (b), 5 (c), 10 (d), and 15 (e) minutes after intravenous
injection of Gd-(DTPA-BMA) (A), Gd-DTPA cystamine copolymer GDCC-18 (B),
and GDCC-60 (C) at a dose of 0.1 mmol-Gd/kg.
Figure 8 Coronal MR images of mouse hearts before (a) and 1 (b), 5 (c), 15 (d),
30 (e), and 60 minutes (f) post intravenous injection of PEGa-Gd-DTPA cystine
copolymer (GDCP) (A), PEGb-GDCP (B), GDCP (C), and DTPA-BMA (D).
Polymeric agents were given at a dose of 0.03 mmol/kg and DTPA-BMA was
given at the standard clinical dose of 0.1 mmol-Gd/kg.International Journal of Nanomedicine 2006:1(1) 38
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of tumor-bearing mice contrast enhanced with GDCEP
(0.1 mmol-Gd/kg) after the mice were treated for a period
of 21 days with saline, a cationic polymer, anti-VEGF
siRNA, and siRNA-polymer complex. Significant contrast
enhancement was observed in the tumor rim of the mice,
which clearly defined tumor size in the mice in different
treatment groups. Mice treated with the siRNA and siRNA-
polymer complexes had much smaller tumor sizes than mice
treated with saline and cationic polymers as shown by
contrast-enhanced MRI.
Conclusion
Polydisulfide Gd(III) chelates have been designed and
synthesized as extracellular biodegradable macromolecular
MRI contrast agents. The disulfide bonds in the polymer
Figure 9 Coronal MR images of mouse hearts before (a) and 2 (b), 5 (c), 15 (d),
30 (e), and 60 minutes (f) post intravenous injection of PEG2000-Gd-DTPA
cystine copolymer (GDCP) (A), PEG1000-GDCP (B), and PEG500-GDCP (C) at a
dose of 0.05 mmol-Gd/kg.
Figure 10 Coronal MR images of tumor-bearing mice before (a) and 5 (b),
15 (c), 30 (d), and 60 (e) minutes after intravenous injection of Gd-DTPA cystine
copolymer (A), Gd-DTPA cystine diethyl ester copolymer (B), Gd-DTPA
cystamine copolymer (C), and Gd-(DTPA-BMA) (D) at a dose of 0.1 mmol-Gd/kg.
stronger and longer contrast enhancement in the blood pool
than PEG2000-GDCP of a lower grafting ratio (0.33), even if
the latter had higher relaxivity (Mohs et al 2004). Both
agents were more effective in contrast-enhanced blood-pool
imaging than GDCP (Mw = 11 400 Da) (Figure 8). With
similar grafting ratios, PEG-GDCP with different PEG sizes
had similar contrast enhancement in the blood pool during
the initial period (2 minutes) post-injection, but the duration
of the contrast enhancement decreased with decreasing size
of PEG (Figure 9). PEG2000-GDCP resulted in more
sustained enhancement than PEG1000-GDCP, while PEG550-
GDCP had the least duration of enhancement.
In tumor MRI, the polydisulfide agents resulted in
significant contrast enhancement in the tumor periphery.
Figure 10 shows the coronal MR images of tumor tissue
contrast enhanced by GDCC, GDCP, GDCEP, and Gd-
(DTPA-BMA) in mice bearing MDA-MB-231 breast
carcinoma xenografts. The biodegradable macromolecular
agents produced more significant contrast enhancement in
the tumor periphery than Gd-(DTPA-BMA). The modified
agents GDCP and GDCEP resulted in more effective
contrast enhancement than GDCC. Contrast enhancement
in the tumor interstitium was less significant, possibly due
to high interstitial fluid pressure, collapsed blood vessels
forced by rapidly growing tumor tissue, and the formation
of necrotic tissue in solid tumor (Padera et al 2004).
The polydisulfide agents provided clear visualization of
the periphery and size of solid tumor, which could be useful
for the evaluation of tumor response to treatment. GDCEP
has been studied in the noninvasive evaluation of the
therapeutic response of solid tumor to an anti-VEGF siRNA
in mice bearing MDA MB-231 breast carcinoma xenografts
(Wang et al 2004). Figure 11 shows the coronal MR imagesInternational Journal of Nanomedicine 2006:1(1) 39
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chains can be readily cleaved by endogenous thiols into
small and excretable Gd(III) complexes. The degradability
of the polydisulfides can be altered by structural
modification of the agents to achieve different in vivo
properties. A pharmacokinetic and biodistribution study
demonstrated that GDCC has a relatively longer plasma
retention time for effective contrast-enhanced MRI and is
rapidly excreted as low molecular-weight Gd(III)
complexes, resulting in minimal long-term Gd(III) tissue
accumulation comparable to Gd(DTPA-BMA). The
structural modification of polydifulfide Gd(III) complexes
can result in biodegradable macromolecular contrast agents
with various enhancement profiles in the blood pool. The
agents are effective for cardiovascular and cancer MR
imaging. The polydisulfide Gd(III) complexes have a great
potential to be developed as safe, effective, biodegradable
macromolecular MRI contrast agents for clinical
applications.
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